Vor Biopharma (VOR) Stock Price, News & Analysis

Company Overview

Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing treatments for patients with hematologic malignancies, including acute myeloid leukemia (AML). The company combines engineered hematopoietic stem cell therapies with targeted cancer medicines in an effort to improve the selectivity and effectiveness of treatment.

Vor’s lead program, trem-cel (formerly known as VOR33), is an investigational gene-edited hematopoietic stem cell therapy designed to eliminate the CD33 protein from blood-forming stem cells. This approach is intended to protect healthy blood cells from CD33-directed therapies, potentially allowing those treatments to target leukemia cells more effectively while supporting recovery of the bone marrow.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Vor Biopharma conducts research and clinical development activities in the United States. Its programs remain investigational and are subject to clinical testing and regulatory review; the company has not established its therapies as approved treatments.

Key Stats

• Today's Range: $21.80 to $23.05
• 50-Day Range: $17.34 to $25.10
• 52-Week Range: $6.50 to $49.95
• Volume: 1.54 million shs
• Average Volume: 703,972 shs
• Market Capitalization: $1.30 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.38
• Consensus Rating: Moderate Buy

Vor Biopharma Stock Analysis - MarketRank™

Vor Biopharma scored higher than 37% of companies evaluated by MarketBeat, and ranked 700th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vor Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 6 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Vor Biopharma has a consensus price target of $43.38, representing about 98.1% upside from its current price of $21.89.

Amount of Analyst Coverage

Vor Biopharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Vor Biopharma are expected to decrease in the coming year, from ($2.56) to ($3.43) per share.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.99% of the float of Vor Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Vor Biopharma has a short interest ratio ("days to cover") of 10.37, which indicates bearish sentiment.

Change versus previous month

Short interest in Vor Biopharma has recently increased by 4.30%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vor Biopharma does not currently pay a dividend.

Dividend Growth

Vor Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

Vor Biopharma has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Vor Biopharma this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for VOR on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Vor Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vor Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,207.00 in company stock.

Percentage Held by Insiders

0.27% of the stock of Vor Biopharma is held by insiders.

Percentage Held by Institutions

97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/17/2026
• Stifel 2026 Virtual Immunology and Inflammation Forum: 9/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VOR
• Previous Symbol: NASDAQ:VOR
• CIK: 1817229
• Web: vorbio.com
• Phone: (617) 655-6580
• Fax: N/A
• Employees: 76
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Vor Biopharma: $43.38
• High Price Target: $64.00
• Low Price Target: $27.00
• Potential Upside/Downside: +98.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 59,160,000
• Free Float: 59,002,000
• Market Cap: $1.30 billion
• Optionable: N/A
• Beta: 1.71